Key features and details
- Rabbit monoclonal [EP2067Y] to Nicotinic Acetylcholine Receptor beta/CHRNB1
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Product nameAnti-Nicotinic Acetylcholine Receptor beta/CHRNB1 antibody [EP2067Y]
See all Nicotinic Acetylcholine Receptor beta/CHRNB1 primary antibodies
DescriptionRabbit monoclonal [EP2067Y] to Nicotinic Acetylcholine Receptor beta/CHRNB1
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
corresponding to Human Nicotinic Acetylcholine Receptor beta/CHRNB1 aa 50-150.
- Human brain lysate.
This product was previously labelled as Nicotinic Acetylcholine Receptor beta
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab76159 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/2000. Predicted molecular weight: 57 kDa.|
FunctionAfter binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Involvement in diseaseDefects in CHRNB1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes.
Defects in CHRNB1 are a cause of congenital myasthenic syndrome with acetylcholine receptor deficiency (ACHRDCMS) [MIM:608931]. ACHRDCMS is a post-synaptic congenital myasthenic syndrome. Mutations underlying AChR deficiency cause a 'loss of function' and show recessive inheritance.
Sequence similaritiesBelongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Beta-1/CHRNB1 sub-subfamily.
Cellular localizationCell junction > synapse > postsynaptic cell membrane. Cell membrane.
- Information by UniProt
- Acetylcholine receptor protein beta chain precursor antibody
- Acetylcholine receptor subunit beta antibody
- ACHB_HUMAN antibody
ab76159 has been referenced in 1 publication.
- Kelly NA et al. Effects of aging and Parkinson's disease on motor unit remodeling: influence of resistance exercise training. J Appl Physiol (1985) 124:888-898 (2018). PubMed: 29357501